ArticleJournal of the American Society of Nephrology : JASN2014
A pegylated leptin antagonist ameliorates CKD-associated cachexia in mice.
Article in Journal of the American Society of Nephrology : JASN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Combating chronic kidney disease-associated cachexia: A literature review of recent therapeutic approaches.BMC nephrology · 2025Review
- Leptin antagonism attenuates hypertension and renal injury in an experimental model of autoimmune disease.Clinical science (London, England : 1979) · 2023Article
- Treatment with fibroblast growth factor 19 increases skeletal muscle fiber size, ameliorates metabolic perturbations and hepatic inflammation in 5/6 nephrectomized mice.Scientific reports · 2023Article
- Growth Hormone Improves Adipose Tissue Browning and Muscle Wasting in Mice with Chronic Kidney Disease-Associated Cachexia.International journal of molecular sciences · 2022Article
- Article
- The role of IL-1 in adipose browning and muscle wasting in CKD-associated cachexia.Scientific reports · 2021Article
- Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease-associated cachexia.The Journal of clinical investigation · 2020Article
- Vitamin D repletion ameliorates adipose tissue browning and muscle wasting in infantile nephropathic cystinosis-associated cachexia.Journal of cachexia, sarcopenia and muscle · 2020Article
- Immunologic and endocrine functions of adipose tissue: implications for kidney disease.Nature reviews. Nephrology · 2018Review
- Mito-TEMPO Alleviates Renal Fibrosis by Reducing Inflammation, Mitochondrial Dysfunction, and Endoplasmic Reticulum Stress.Oxidative medicine and cellular longevity · 2018Article
- The potential role of leptin in tumor invasion and metastasis.Cytokine & growth factor reviews · 2017Review
- Inflammatory Cytokines as Uremic Toxins: "Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son".Toxins · 2017Review
- Lack of hepcidin ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease.American journal of physiology. Renal physiology · 2016Article
- Inflammation and nutrition in children with chronic kidney disease.World journal of nephrology · 2016Review
- Muscle wasting and adipose tissue browning in infantile nephropathic cystinosis.Journal of cachexia, sarcopenia and muscle · 2016Article
- PTH/PTHrP Receptor Mediates Cachexia in Models of Kidney Failure and Cancer.Cell metabolism · 2016Article
- Genetically altering organismal metabolism by leptin-deficiency benefits a mouse model of amyotrophic lateral sclerosis.Human molecular genetics · 2014Article
- Mechanisms of muscle wasting in chronic kidney disease.Nature reviews. Nephrology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
Elevated serum leptin levels correlate with inflammation and predict changes in lean body mass in patients with CKD, and activation of the melanocortin system by leptin signaling mediates the pathophysiology of CKD-associated cachexia. We tested whether treatment with a pegylated leptin receptor antagonist (PLA) attenuates cachexia in mice with CKD. CKD and Sham mice received vehicle or PLA (2 or 7 mg/kg per day). At these doses, PLA did not influence serum leptin levels in mice. Treatment with 7 mg/kg per day PLA stimulated appetite and weight gain, improved lean mass and muscle function, reduced energy expenditure, and normalized the levels of hepatic TNF-α and IL-6 mRNA in mice with CKD. Furthermore, treatment with 7 mg/kg per day PLA attenuated the CKD-associated increase in the transcriptional and protein abundance of uncoupling proteins that mediates thermogenesis, and it normalized the molecular signatures of processes associated with muscle wasting in CKD, including proteolysis, myogenesis and muscle regeneration, and expression of proinflammatory muscle cytokines, such as IL-1α, -1β, and -6 and TNF-α. Our results suggest that leptin antagonism may represent a viable therapeutic strategy for cachexia in CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.